LATEST

    Vinco Ventures (BBIG) announces Q1 results; revenue up 349%

    May 24, 2022

    SIGA technologies (SIGA) stock gains as monkeypox cases rise

    May 23, 2022

    Ross Stores (ROST) sinks on lower FY22 outlook; down 24%

    May 19, 2022

    Jumia Technologies (JMIA) stock gains 25% after earnings

    May 17, 2022

    Sea Ltd (SE) stock gains over 10% on strong earnings

    May 17, 2022
    Legal
    Privacy Policy
    Cookie Policy
    Terms and Conditions
    Twitter Facebook Instagram YouTube LinkedIn
    Facebook Twitter Instagram YouTube LinkedIn
    Rising CandleRising Candle
    • Home
    • Market News

      Sea Ltd (SE) stock gains over 10% on strong earnings

      May 17, 2022

      Alibaba (BABA) stock soars after JPMorgan raises Chinese tech stock ratings

      May 17, 2022

      Cornerstone (CLM) stock gains after right offering closure

      May 16, 2022

      GameStop (GME) appoints new CFO, stock gains continue

      May 16, 2022

      DWAC stocks rise in premarket after filing the S-4 form

      May 16, 2022
    • Earnings
    • Business

      SIGA technologies (SIGA) stock gains as monkeypox cases rise

      May 23, 2022

      Elon Musk puts the Twitter deal “temporarily on hold”; but still committed to acquire

      May 13, 2022

      U.S. unemployment claims rise again

      May 12, 2022

      Biohaven Pharma (BHVN) reports FY22 Q1 earnings; Pfizer will buy it

      May 10, 2022

      Meta announces testing NFTs on Instagram

      May 9, 2022
    • Cryptocurrency
    • Forex
    Rising CandleRising Candle
    Home » Novavax (NVAX) Q1 results miss estimates, stock tanks
    Market News

    Novavax (NVAX) Q1 results miss estimates, stock tanks

    Kritika MehtaBy Kritika MehtaMay 9, 2022Updated:May 9, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Novavax, Inc. (NASDAQ: NVAX) released its FY22 Q1 earnings report on Monday, May 6, 2022, after the market closed. Here is an overview of the essential disclosure.

    • Revenue: $704 million reported vs. $878.11 million expected
    • EPS: $2.56 adjusted vs. $3.33 expected
    • Net Income: $203 million

    The NVAX stock was down by 8.21% and traded at $48.89 (down by 4.37 points) in the extended trading session on Tuesday.

    Financial Highlights
    • Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company.
    • Reiterating full year 2022 total revenue guidance of between $4 and $5 billion.
    • Continued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid™ into European Union, Canada, South Korea, Australia Thailand, Singapore and New Zealand.
    • Submitted request for EUA to U.S. FDA for NVX-CoV2373, with FDA Advisory Committee meeting scheduled for June 7.
    • Announced positive Phase 1/2 results of COVID-19-Influenza Combination vaccine candidate confirming feasibility of approach.
    CEO’s Statement

    “Novavax has been successful in launching our protein-based COVID-19 vaccine worldwide and executing on our plans for ongoing label expansions for pediatrics and homologous and heterologous boosting. Reinforced by our first profitable quarter, with $704 million in revenue, we are continuing our robust commercial rollout. Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-Influenza Combination vaccine candidate.”

    said Stanley C. Erck, President and Chief Executive Officer, Novavax
    Analysts Estimate

    The Zacks Consensus Estimate for the earnings per share (EPS) was pinned at $3.33. This indicated a massive decline of 209.18% year-over-year. Moreover, it also suggested a huge gain of 142.7% than that of the last quarter.

    The Earnings Expected Surprise Prediction was 10.13%, which suggested that the consensus did expect Novavax to meet as well as beat the estimates for the first quarter. Moreover, the estimated revenue was pegged at $878.11 million. This suggested a substantial decline of 96.34% year-over-year.

    Earnings History

    Novavax, the pharmaceutical company, reported a revenue of $222 million for the fourth quarter and $1.1 billion for the full year. Earnings per share of $ 11.18 for the fourth quarter and $23.44 for the full year.

    In the third quarter of 2021, Novavax reported a net loss of $322.4 million, or $4.31 per share, compared to a net loss of $197.3 million, or $3.21 per share, in the third quarter of 2020.

    In the third quarter of 2021, Novavax’s revenue was $178.8 million, up from $157.0 million in the same period in 2020. This increase was due to increased development activities for NVX-CoV2373 for services performed under the US government agreement and royalties under Novavax Licensing agreements.

    Earnings Forecast

    Zacks analysts estimate the EPS to be at $0.25 in the second quarter of FY22, indicating a huge decline of 30.56% year-over-year. Moreover, the revenue is estimated at $1.12 million, indicating a growth of 277.31% from this year.

    Novavax earnings Novavax inc Novavax q1 earnings 2022
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Kritika Mehta

    Related Posts

    Sea Ltd (SE) stock gains over 10% on strong earnings

    May 17, 2022

    Alibaba (BABA) stock soars after JPMorgan raises Chinese tech stock ratings

    May 17, 2022

    Cornerstone (CLM) stock gains after right offering closure

    May 16, 2022

    GameStop (GME) appoints new CFO, stock gains continue

    May 16, 2022
    Add A Comment

    Comments are closed.

    Trending

    SIGA technologies (SIGA) stock gains as monkeypox cases rise

    May 23, 2022

    Ross Stores (ROST) sinks on lower FY22 outlook; down 24%

    May 19, 2022

    Jumia Technologies (JMIA) stock gains 25% after earnings

    May 17, 2022

    Weber (WEBR) stock slumps after weak earnings

    May 16, 2022

    Wix.com shares drop 10% in premarket after missing estimates

    May 16, 2022

    Subscribe to Updates

    Get the latest Business and Finance news only at Investor's pulse

    Advertisement
    Editor's Picks

    AMC named ‘100 Most Influential Companies of 2022’ by Time Magazine

    March 31, 2022

    BuzzFeed released first earnings report after going public; revenue grew 24% YOY

    March 22, 2022

    U.S. jobless claims dip to a 2.5-month low

    March 17, 2022

    FOMC: Recent updates you need to know!

    March 17, 2022

    Your source for the latest US stock market and business news.

    Connect with us:

    Facebook Twitter Instagram YouTube LinkedIn Reddit

    Subscribe to Updates

    Subscribe to get weekly updates on what happened on the Stock Market and insights into where to invest.

    Legal
    Privacy Policy
    Cookie Policy
    Terms and Conditions
    © 2022 Investor's Pulse. All Rights Reserved.
    • Home

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT
    Go to mobile version